<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01335971</url>
  </required_header>
  <id_info>
    <org_study_id>1U01HL105569</org_study_id>
    <secondary_id>RFA-HL-10-003</secondary_id>
    <nct_id>NCT01335971</nct_id>
    <nct_alias>NCT01318603</nct_alias>
  </id_info>
  <brief_title>Broccoli Sprout Extracts Trial to See if NRF2 is Enhanced by Sulforaphane Treatment in Patients With COPD</brief_title>
  <acronym>BEST</acronym>
  <official_title>Enhancing Nrf2 by Sulforaphane Treatment in COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Temple University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>State University of New York at Buffalo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evidence from investigators' group has shown that chronic obstructive pulmonary disease
      (COPD) patients have impairment of antioxidant defenses which are caused by a defect in
      activity of Nrf2. This trial focuses on sulforaphane, a derivative of cruciferous vegetables,
      which is a potent stimulator of Nrf2 activity. The investigators want to investigate whether
      ingestion of sulforaphane by COPD patients will increase Nrf2 activity and expression of
      downstream antioxidants. Accordingly, the investigators are conducting a placebo-controlled
      randomized proof of principle trial of two oral doses of sulforaphane, 25 and 150 micromoles,
      for 4 weeks in 90 COPD patients. The investigators' goal is to establish a safe and tolerable
      dose of sulforaphane that effects in vivo antioxidants via Nrf2, then the investigators will
      have a novel candidate treatment for longer-term efficacy trials.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic Obstructive Pulmonary Disease (COPD) is a major cause of morbidity and mortality in
      the United States and is a growing cause of chronic disease internationally. Presently, there
      are limited treatment options for this disease to modify the progression of airflow
      obstruction and decrease periodic exacerbations. Recent evidence has emphasized the central
      role of oxidative stress as a mechanism of COPD pathobiology. Evidence from investigators'
      group has shown that COPD patients and animals exposed to cigarette smoke have impairment of
      antioxidant defenses which are caused by a defect in activity of nuclear factor erythroid 2
      like 2 (Nrf2), a prolific regulator of anti-oxidant enzymes, glutathione homeostasis, and
      cytoprotective proteins. Activation of Nrf2 protects mice with chronic smoke exposure from
      developing emphysema, decreases oxidative stress, increases proteasomal anti-apoptotic
      cytoprotective responses, improves bacterial phagocytosis and killing, and reverses
      tobacco-smoke induced corticosteroid resistance. Similarly, in vitro Nrf2 activation in human
      COPD lung cells has shown improved cytoprotection, improved bacterial clearance, and
      restoration of steroid sensitivity. This trial focuses on sulforaphane, a derivative of
      cruciferous vegetables, which is a potent in vitro and in vivo stimulator of Nrf2 activity.
      The investigators want to investigate whether ingestion of sulforaphane by chronic
      obstructive pulmonary disease (COPD) patients will increase Nrf2 activity and expression of
      downstream antioxidants in alveolar macrophages and bronchial epithelial cells. Accordingly,
      the investigators are conducting a placebo-controlled randomized proof of principle trial of
      two oral doses of sulforaphane, 25 and 150 micromoles, for 4 weeks in 90 COPD patients.
      Collections of alveolar macrophages by Bronchoalveolar lavage (BAL), bronchial epithelial
      cells by endobronchial brushings will be performed at baseline and 4 weeks. Other
      bio-specimens will include nasal epithelial cells, Peripheral Blood Monocyte Collection
      (PBMCs), and expired breath condensate (EBC). The investigators' goal is to establish a safe
      and tolerable dose of sulforaphane that effects in vivo antioxidants via Nrf2, then the
      investigators will have a novel candidate treatment for longer-term efficacy trials.
      Ancillary studies are proposed to explore the efficacy and mechanisms of sulforaphane to
      increase bacterial clearance and to restore steroid sensitivity in COPD lung cells.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2010</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Alveolar Macrophage Expression of Nrf2 and Associated Genes at 4 Weeks</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>The first primary design variable is the change from baseline in nuclear factor erythroid 2 like 2 (Nrf2) expression in alveolar macrophages (AM) at 4 weeks by analysing Nrf2 protein and expression of a panel of Nrf2 regulated genes.Three participants - one from each treatment group - were unable to complete follow-up bronchoalveolar lavage for primary outcome data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Bronchial Epithelial Cell Expression of Nrf2 at 4 Weeks</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>The second primary design variable is the change from baseline in nuclear factor erythroid 2 like 2 (Nrf2) expression in bronchial epithelial cells (BEC) at 4 weeks by analysing Nrf2 protein. Three participants - one from each treatment group - were unable to complete follow-up bronchoalveolar lavage for primary outcome data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Bronchial Epithelial Cell Expression of NQ01 and Keap1 at 4 Weeks</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>The third primary design variable is the change from baseline in NAD(P)H Quinone Dehydrogenase 1 (NQ01) and Kelch Like ECH Associated Protein 1 (Keap1) expression in bronchial epithelial cells (BEC) at 4 weeks. Three participants - one from each treatment group - were unable to complete follow-up bronchoalveolar lavage for primary outcome data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Bronchial Epithelial Cell Expression of HO1 at 4 Weeks</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>The fourth primary design variable is the change from baseline in expression of Heme Oxygenase 1 (HO1) in bronchial epithelial cells (BEC) at 4 weeks. Three participants - one from each treatment group - were unable to complete follow-up bronchoalveolar lavage for primary outcome data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Bronchial Epithelial Cell Expression of AKR1C1 at 4 Weeks</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>The fifth primary design variable is the change from baseline in expression of Aldo-Keto Reductase Family 1 Member C1 (AKR1C1) in bronchial epithelial cells (BEC) at 4 weeks. Three participants - one from each treatment group - were unable to complete follow-up bronchoalveolar lavage for primary outcome data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Bronchial Epithelial Cell Expression of AKR1C3 at 4 Weeks</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>The sixth primary design variable is the change from baseline in expression of Aldo-Keto Reductase Family 1 Member C3 (AKR1C3) in bronchial epithelial cells (BEC) at 4 weeks. Three participants - one from each treatment group - were unable to complete follow-up bronchoalveolar lavage for primary outcome data.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fold-change in Isoprostane Concentrations (Follow-up to Baseline)</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Isoprostane, an oxidant stress indicator, was measured in expired breath condensate at baseline and 4 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fold-change in Serum Inflammatory Marker Concentrations (Follow-up to Baseline)</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Inflammatory markers were measured in serum samples derived from venipuncture at baseline and 4 weeks in the serum of the participants of the trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fold-change in Inflammatory Marker Concentrations in Bronchial Alveolar Lavage (Follow-up to Baseline) by Treatment Group</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Inflammatory markers were measured in bronchial alveolar lavage samples at baseline and 4 weeks in the participants of this trial who had bronchoalveolar lavage samples obtained.Three participants - one from each treatment group - were unable to complete follow-up bronchoalveolar lavage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fold-change in Plasma Inflammatory Marker Concentrations (Follow-up to Baseline)</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Inflammatory markers were measured in plasma at baseline and 4 weeks. Thiobarbituric acid reactive substances were measured in nmol malondialdehyde (MDA)/mL.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Sulforaphane 25</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 micromoles (4.4 mg) sulforaphane daily by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sulforaphane 150</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>150 micromoles (26.6 mg) sulforaphane daily by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Microcrystalline cellulose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulforaphane 25</intervention_name>
    <description>25 micromoles (4.4 mg) sulforaphane daily by mouth</description>
    <arm_group_label>Sulforaphane 25</arm_group_label>
    <other_name>This is derived from broccoli sprouts.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sulforaphane 150</intervention_name>
    <description>150 micromoles (26.6 mg) sulforaphane daily by mouth</description>
    <arm_group_label>Sulforaphane 150</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Microcrystalline cellulose once daily by mouth</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 40 years or greater, either sex

          -  10 or more pack-years smoking history

          -  Physician diagnosed COPD

          -  Post bronchodilator Forced expiratory volume in 1 second (FEV1)/ forced expiratory
             vital capacity (FVC) ratio &lt; 0.70

          -  FEV1 40-80 % predicted

          -  Willingness to ingest no more than 1 serving of cruciferous vegetables per week during
             run-in and treatment periods

          -  Ability and willingness to provide informed consent

        Exclusion Criteria:

          -  COPD exacerbation within preceding 6 weeks requiring treatment

          -  Significant respiratory (other than COPD), cardiovascular, neuropsychiatric, renal,
             gastrointestinal, or genitourinary disease that would interfere with participation in
             the study or interpretation of the results.

          -  Acute Myocardial infarction (MI) or Acute Coronary syndrome within 6 prior months

          -  Cancer (other than skin or localized prostate) within preceding 5 years

          -  Child-bearing potential with lack of adequate contraception, Pregnancy or lactation.
             Acceptable forms of birth control include abstinence, hysterectomy, tubal ligation,
             two of the following: vasectomy, condom, diaphragm, intrauterine device, oral or
             implanted contraceptives, or spermicide.

          -  Allergy to local anesthesia

          -  Resting hypoxemia (O2 saturation &lt; 90%)

          -  Glomerular Filtration Rate (GFR) &lt; 30

          -  Liver enzymes four times upper normal

          -  Current use of warfarin for any indication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janet T Holbrook, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Bloomberg School of Public Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University at Baffalo, The State University of New York</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2011</study_first_submitted>
  <study_first_submitted_qc>April 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2011</study_first_posted>
  <results_first_submitted>August 25, 2016</results_first_submitted>
  <results_first_submitted_qc>April 11, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 19, 2017</results_first_posted>
  <last_update_submitted>April 11, 2017</last_update_submitted>
  <last_update_submitted_qc>April 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Nrf2</keyword>
  <keyword>Sulforaphane</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulforafan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The primary method of data-sharing will be through the traditional mechanism of publication of results in the peer-reviewed medical literature. Following publication of the main results, in accordance with NIH policy, a de-identified, HIPAA-compliant limited use dataset will be made available to qualified investigators who have Institutional Review Board approval and sign a data-use agreement. De-identified specimens collected in the study that are not analyzed for the main study will be made available to qualified investigators along with a limited use dataset in line with University and Office of Human Research Protections guidelines with a materials transfer agreement and/or data-use agreement as applicable. The Center for Clinical Trials has extensive experience in preparation of limited use datasets, and maintains policies and model agreements for data-use agreements and materials-transfer agreements.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Microcrystalline cellulose
Placebo: Microcrystalline cellulose once daily by mouth</description>
        </group>
        <group group_id="P2">
          <title>Sulforaphane 25</title>
          <description>25 micromoles (4.4 mg) sulforaphane daily by mouth
Sulforaphane 25: 25 micromoles (4.4 mg) sulforaphane daily by mouth</description>
        </group>
        <group group_id="P3">
          <title>Sulforaphane 150</title>
          <description>150 micromoles (26.6 mg) sulforaphane daily by mouth
Sulforaphane 150: 150 micromoles (26.6 mg) sulforaphane daily by mouth</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not complete bronchoscopy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Microcrystalline cellulose
Placebo: Microcrystalline cellulose once daily by mouth</description>
        </group>
        <group group_id="B2">
          <title>Sulforaphane 25</title>
          <description>25 micromoles (4.4 mg) sulforaphane daily by mouth
Sulforaphane 25: 25 micromoles (4.4 mg) sulforaphane daily by mouth</description>
        </group>
        <group group_id="B3">
          <title>Sulforaphane 150</title>
          <description>150 micromoles (26.6 mg) sulforaphane daily by mouth
Sulforaphane 150: 150 micromoles (26.6 mg) sulforaphane daily by mouth</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="29"/>
            <count group_id="B4" value="89"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" lower_limit="52" upper_limit="67"/>
                    <measurement group_id="B2" value="59" lower_limit="54" upper_limit="65"/>
                    <measurement group_id="B3" value="56" lower_limit="52" upper_limit="62"/>
                    <measurement group_id="B4" value="58" lower_limit="54" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Chronic obstructive pulmonary disease (COPD) characteristics</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>10 or more pack years of smoking history</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoke cigarettes now</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoke 10 or more cigarettes a day now</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COPD exacerbation in last 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Post bronchodilator FEV1</title>
          <description>Forced expiratory volume in 1 second (FEV1) after administration of bronchodilator</description>
          <units>percent predicted</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="54" upper_limit="70"/>
                    <measurement group_id="B2" value="54" lower_limit="50" upper_limit="65"/>
                    <measurement group_id="B3" value="65" lower_limit="55" upper_limit="72"/>
                    <measurement group_id="B4" value="61" lower_limit="53" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Post bronchodilator FEV1/FVC ratio</title>
          <description>Ratio of forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) after bronchodilation</description>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.56" lower_limit="0.51" upper_limit="0.63"/>
                    <measurement group_id="B2" value="0.52" lower_limit="0.47" upper_limit="0.59"/>
                    <measurement group_id="B3" value="0.57" lower_limit="0.50" upper_limit="0.63"/>
                    <measurement group_id="B4" value="0.56" lower_limit="0.48" upper_limit="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO)</title>
          <description>DLCO: Diffusing capacity of the lungs for carbon monoxide measured by the single breath technique in accordance with American Thoracic Society standards</description>
          <units>mL/mmHg/min</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.8" lower_limit="11.8" upper_limit="19.5"/>
                    <measurement group_id="B2" value="15.7" lower_limit="12.1" upper_limit="19.3"/>
                    <measurement group_id="B3" value="16.3" lower_limit="12.3" upper_limit="21.4"/>
                    <measurement group_id="B4" value="15.7" lower_limit="12.1" upper_limit="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pulse oximetry (SpO2)</title>
          <units>Percentage of oxyhemoglobin</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95" lower_limit="94" upper_limit="97"/>
                    <measurement group_id="B2" value="96" lower_limit="95" upper_limit="97"/>
                    <measurement group_id="B3" value="96" lower_limit="94" upper_limit="97"/>
                    <measurement group_id="B4" value="96" lower_limit="94" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pulmonary function measures</title>
          <description>Values were determined using either helium dilution or plethysmography methods, depending on equipment available at study sites. Lung volumes were measured in accordance with local hospital procedures.</description>
          <units>Liters</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <title>Total lung capacity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.0" lower_limit="4.7" upper_limit="7.3"/>
                    <measurement group_id="B2" value="5.5" lower_limit="4.9" upper_limit="6.8"/>
                    <measurement group_id="B3" value="6.3" lower_limit="5.7" upper_limit="7.0"/>
                    <measurement group_id="B4" value="6.0" lower_limit="5.0" upper_limit="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slow vital capacity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.1" lower_limit="2.4" upper_limit="4.1"/>
                    <measurement group_id="B2" value="3.0" lower_limit="2.8" upper_limit="3.7"/>
                    <measurement group_id="B3" value="3.7" lower_limit="3.1" upper_limit="4.4"/>
                    <measurement group_id="B4" value="3.3" lower_limit="2.7" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Forced residual capacity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.6" lower_limit="3.1" upper_limit="4.5"/>
                    <measurement group_id="B2" value="3.6" lower_limit="3.0" upper_limit="4.1"/>
                    <measurement group_id="B3" value="3.4" lower_limit="3.0" upper_limit="3.9"/>
                    <measurement group_id="B4" value="3.5" lower_limit="3.0" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Residual volume</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.6" lower_limit="2.5" upper_limit="3.4"/>
                    <measurement group_id="B2" value="2.6" lower_limit="2.2" upper_limit="3.5"/>
                    <measurement group_id="B3" value="2.7" lower_limit="2.3" upper_limit="2.9"/>
                    <measurement group_id="B4" value="2.6" lower_limit="2.2" upper_limit="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Use of respiratory medications in prior 2 weeks</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Short-acting beta-agonist</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Long-acting beta-agonist</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Long-acting beta-agonist &amp; inhaled corticosteroid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Long-acting anticholinergic bronchodilator</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Medical Research Council Dyspnea Score</title>
          <description>Minimum score 1, maximum score 5. Higher values represent a worse outcome.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="B2" value="2" lower_limit="2" upper_limit="3"/>
                    <measurement group_id="B3" value="2" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="B4" value="2" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>St Georges Respiratory Questionnaire</title>
          <description>Scales, ranges, and descriptors:
All scores are expressed as a percentage of overall impairment where 100 is the worst possible health status and 0 is the best possible health status.
Total score (all items) summarizes the impact of the disease on overall health status Symptoms score (Q1-8) looks at the effect of respiratory symptoms, their frequency and severity.
Activity score (Q11-17, 37-45) measures activities causing or limited by breathlessness Impacts score (Q18-36, 46-52) covers a range of aspects re: social functioning and psychological disturbances resulting from airways disease</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <title>Total score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43" lower_limit="24" upper_limit="58"/>
                    <measurement group_id="B2" value="47" lower_limit="27" upper_limit="56"/>
                    <measurement group_id="B3" value="39" lower_limit="24" upper_limit="54"/>
                    <measurement group_id="B4" value="40" lower_limit="26" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptoms score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" lower_limit="32" upper_limit="70"/>
                    <measurement group_id="B2" value="55" lower_limit="43" upper_limit="68"/>
                    <measurement group_id="B3" value="50" lower_limit="31" upper_limit="57"/>
                    <measurement group_id="B4" value="52" lower_limit="36" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activity score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" lower_limit="30" upper_limit="74"/>
                    <measurement group_id="B2" value="60" lower_limit="47" upper_limit="74"/>
                    <measurement group_id="B3" value="50" lower_limit="41" upper_limit="73"/>
                    <measurement group_id="B4" value="55" lower_limit="36" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Impacts score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27" lower_limit="17" upper_limit="44"/>
                    <measurement group_id="B2" value="34" lower_limit="15" upper_limit="46"/>
                    <measurement group_id="B3" value="26" lower_limit="13" upper_limit="42"/>
                    <measurement group_id="B4" value="28" lower_limit="15" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Alveolar Macrophage Expression of Nrf2 and Associated Genes at 4 Weeks</title>
        <description>The first primary design variable is the change from baseline in nuclear factor erythroid 2 like 2 (Nrf2) expression in alveolar macrophages (AM) at 4 weeks by analysing Nrf2 protein and expression of a panel of Nrf2 regulated genes.Three participants - one from each treatment group - were unable to complete follow-up bronchoalveolar lavage for primary outcome data.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>Number of participants analyzed based on number of individuals with alveolar macrophage samples in which assays could be successfully performed. Assays failed for two participants in the placebo group, one in the 25 micromole group, and one in the 150 micromole group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Microcrystalline cellulose
Placebo: Microcrystalline cellulose once daily by mouth</description>
          </group>
          <group group_id="O2">
            <title>Sulforaphane 25</title>
            <description>25 micromoles (4.4 mg) sulforaphane daily by mouth
Sulforaphane 25: 25 micromoles (4.4 mg) sulforaphane daily by mouth</description>
          </group>
          <group group_id="O3">
            <title>Sulforaphane 150</title>
            <description>150 micromoles (26.6 mg) sulforaphane daily by mouth
Sulforaphane 150: 150 micromoles (26.6 mg) sulforaphane daily by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alveolar Macrophage Expression of Nrf2 and Associated Genes at 4 Weeks</title>
          <description>The first primary design variable is the change from baseline in nuclear factor erythroid 2 like 2 (Nrf2) expression in alveolar macrophages (AM) at 4 weeks by analysing Nrf2 protein and expression of a panel of Nrf2 regulated genes.Three participants - one from each treatment group - were unable to complete follow-up bronchoalveolar lavage for primary outcome data.</description>
          <population>Number of participants analyzed based on number of individuals with alveolar macrophage samples in which assays could be successfully performed. Assays failed for two participants in the placebo group, one in the 25 micromole group, and one in the 150 micromole group.</population>
          <units>fold change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NQ01</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" lower_limit="0.53" upper_limit="1.09"/>
                    <measurement group_id="O2" value="1.03" lower_limit="0.56" upper_limit="1.60"/>
                    <measurement group_id="O3" value="0.94" lower_limit="0.59" upper_limit="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HO1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" lower_limit="0.69" upper_limit="1.34"/>
                    <measurement group_id="O2" value="0.98" lower_limit="0.83" upper_limit="1.31"/>
                    <measurement group_id="O3" value="1.06" lower_limit="0.68" upper_limit="1.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AKR1C1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" lower_limit="0.46" upper_limit="1.27"/>
                    <measurement group_id="O2" value="1.13" lower_limit="0.38" upper_limit="1.99"/>
                    <measurement group_id="O3" value="0.71" lower_limit="0.56" upper_limit="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AKR1C3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" lower_limit="0.76" upper_limit="1.37"/>
                    <measurement group_id="O2" value="1.02" lower_limit="0.67" upper_limit="1.31"/>
                    <measurement group_id="O3" value="0.87" lower_limit="0.40" upper_limit="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nrf2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14" lower_limit="0.79" upper_limit="1.52"/>
                    <measurement group_id="O2" value="1.05" lower_limit="0.87" upper_limit="1.47"/>
                    <measurement group_id="O3" value="1.13" lower_limit="0.74" upper_limit="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Keap1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" lower_limit="0.66" upper_limit="1.17"/>
                    <measurement group_id="O2" value="0.99" lower_limit="0.82" upper_limit="1.11"/>
                    <measurement group_id="O3" value="1.06" lower_limit="0.59" upper_limit="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Applies to gene expression of NAD(P)H Quinone Dehydrogenase 1 (NQ01) in alveolar macrophages</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.45</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Applies to gene expression of Heme Oxygenase 1 (HO1) in alveolar macrophages</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.40</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Applies to gene expression of Aldo-Keto Reductase Family 1 Member C1 (AKR1C1) in alveolar macrophages</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.75</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Applies to gene expression of Aldo-Keto Reductase Family 1 Member C3 (AKR1C3) in alveolar macrophages</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.49</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Applies to gene expression of nuclear factor erythroid 2 like 2 (Nrf2) in alveolar macrophages</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.88</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Applies to gene expression of Kelch Like ECH Associated Protein 1 (Keap1) in alveolar macrophages</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.71</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Bronchial Epithelial Cell Expression of Nrf2 at 4 Weeks</title>
        <description>The second primary design variable is the change from baseline in nuclear factor erythroid 2 like 2 (Nrf2) expression in bronchial epithelial cells (BEC) at 4 weeks by analysing Nrf2 protein. Three participants - one from each treatment group - were unable to complete follow-up bronchoalveolar lavage for primary outcome data.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>Number of participants analyzed based on number of individuals with bronchial epithelial samples in which assays could be successfully performed. Assays failed for one participant in the placebo group and one in the 25 micromole group..</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Microcrystalline cellulose
Placebo: Microcrystalline cellulose once daily by mouth</description>
          </group>
          <group group_id="O2">
            <title>Sulforaphane 25</title>
            <description>25 micromoles (4.4 mg) sulforaphane daily by mouth
Sulforaphane 25: 25 micromoles (4.4 mg) sulforaphane daily by mouth</description>
          </group>
          <group group_id="O3">
            <title>Sulforaphane 150</title>
            <description>150 micromoles (26.6 mg) sulforaphane daily by mouth
Sulforaphane 150: 150 micromoles (26.6 mg) sulforaphane daily by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Bronchial Epithelial Cell Expression of Nrf2 at 4 Weeks</title>
          <description>The second primary design variable is the change from baseline in nuclear factor erythroid 2 like 2 (Nrf2) expression in bronchial epithelial cells (BEC) at 4 weeks by analysing Nrf2 protein. Three participants - one from each treatment group - were unable to complete follow-up bronchoalveolar lavage for primary outcome data.</description>
          <population>Number of participants analyzed based on number of individuals with bronchial epithelial samples in which assays could be successfully performed. Assays failed for one participant in the placebo group and one in the 25 micromole group..</population>
          <units>fold change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" lower_limit="0.88" upper_limit="1.30"/>
                    <measurement group_id="O2" value="1.06" lower_limit="0.92" upper_limit="1.28"/>
                    <measurement group_id="O3" value="1.06" lower_limit="0.76" upper_limit="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Applies to gene expression of Nrf2 in bronchial epithelial cells</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.68</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Bronchial Epithelial Cell Expression of NQ01 and Keap1 at 4 Weeks</title>
        <description>The third primary design variable is the change from baseline in NAD(P)H Quinone Dehydrogenase 1 (NQ01) and Kelch Like ECH Associated Protein 1 (Keap1) expression in bronchial epithelial cells (BEC) at 4 weeks. Three participants - one from each treatment group - were unable to complete follow-up bronchoalveolar lavage for primary outcome data.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>Number of participants analyzed based on number of individuals with bronchial epithelial samples in which assays could be successfully performed. Assays failed for two participants in the placebo group and one in the 150 micromole group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Microcrystalline cellulose
Placebo: Microcrystalline cellulose once daily by mouth</description>
          </group>
          <group group_id="O2">
            <title>Sulforaphane 25</title>
            <description>25 micromoles (4.4 mg) sulforaphane daily by mouth
Sulforaphane 25: 25 micromoles (4.4 mg) sulforaphane daily by mouth</description>
          </group>
          <group group_id="O3">
            <title>Sulforaphane 150</title>
            <description>150 micromoles (26.6 mg) sulforaphane daily by mouth
Sulforaphane 150: 150 micromoles (26.6 mg) sulforaphane daily by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Bronchial Epithelial Cell Expression of NQ01 and Keap1 at 4 Weeks</title>
          <description>The third primary design variable is the change from baseline in NAD(P)H Quinone Dehydrogenase 1 (NQ01) and Kelch Like ECH Associated Protein 1 (Keap1) expression in bronchial epithelial cells (BEC) at 4 weeks. Three participants - one from each treatment group - were unable to complete follow-up bronchoalveolar lavage for primary outcome data.</description>
          <population>Number of participants analyzed based on number of individuals with bronchial epithelial samples in which assays could be successfully performed. Assays failed for two participants in the placebo group and one in the 150 micromole group.</population>
          <units>fold change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NQ01</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" lower_limit="0.83" upper_limit="1.50"/>
                    <measurement group_id="O2" value="1.12" lower_limit="0.89" upper_limit="1.53"/>
                    <measurement group_id="O3" value="0.96" lower_limit="0.65" upper_limit="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KEAP1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" lower_limit="0.71" upper_limit="1.54"/>
                    <measurement group_id="O2" value="1.39" lower_limit="0.99" upper_limit="2.24"/>
                    <measurement group_id="O3" value="0.87" lower_limit="0.58" upper_limit="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Applies to gene expression of NAD(P)H Quinone Dehydrogenase 1 (NQ01) in bronchial epithelial cells</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.69</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Applies to gene expression of Kelch Like ECH Associated Protein 1 (Keap1) in bronchial epithelial cells</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Bronchial Epithelial Cell Expression of HO1 at 4 Weeks</title>
        <description>The fourth primary design variable is the change from baseline in expression of Heme Oxygenase 1 (HO1) in bronchial epithelial cells (BEC) at 4 weeks. Three participants - one from each treatment group - were unable to complete follow-up bronchoalveolar lavage for primary outcome data.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>Number of participants analyzed based on number of individuals with bronchial epithelial samples in which assays could be successfully performed. Assays failed for one participant in the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Microcrystalline cellulose
Placebo: Microcrystalline cellulose once daily by mouth</description>
          </group>
          <group group_id="O2">
            <title>Sulforaphane 25</title>
            <description>25 micromoles (4.4 mg) sulforaphane daily by mouth
Sulforaphane 25: 25 micromoles (4.4 mg) sulforaphane daily by mouth</description>
          </group>
          <group group_id="O3">
            <title>Sulforaphane 150</title>
            <description>150 micromoles (26.6 mg) sulforaphane daily by mouth
Sulforaphane 150: 150 micromoles (26.6 mg) sulforaphane daily by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Bronchial Epithelial Cell Expression of HO1 at 4 Weeks</title>
          <description>The fourth primary design variable is the change from baseline in expression of Heme Oxygenase 1 (HO1) in bronchial epithelial cells (BEC) at 4 weeks. Three participants - one from each treatment group - were unable to complete follow-up bronchoalveolar lavage for primary outcome data.</description>
          <population>Number of participants analyzed based on number of individuals with bronchial epithelial samples in which assays could be successfully performed. Assays failed for one participant in the placebo group.</population>
          <units>fold change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" lower_limit="0.60" upper_limit="1.23"/>
                    <measurement group_id="O2" value="1.12" lower_limit="0.82" upper_limit="1.67"/>
                    <measurement group_id="O3" value="0.93" lower_limit="0.62" upper_limit="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Applies to gene expression of Heme Oxygenase 1 (HO1) in bronchial epithelial cells</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.53</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Bronchial Epithelial Cell Expression of AKR1C1 at 4 Weeks</title>
        <description>The fifth primary design variable is the change from baseline in expression of Aldo-Keto Reductase Family 1 Member C1 (AKR1C1) in bronchial epithelial cells (BEC) at 4 weeks. Three participants - one from each treatment group - were unable to complete follow-up bronchoalveolar lavage for primary outcome data.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>Number of participants analyzed based on number of individuals with alveolar macrophage samples in which assays could be successfully performed. Assays failed for two participants in the placebo group and two in the 150 micromole group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Microcrystalline cellulose
Placebo: Microcrystalline cellulose once daily by mouth</description>
          </group>
          <group group_id="O2">
            <title>Sulforaphane 25</title>
            <description>25 micromoles (4.4 mg) sulforaphane daily by mouth
Sulforaphane 25: 25 micromoles (4.4 mg) sulforaphane daily by mouth</description>
          </group>
          <group group_id="O3">
            <title>Sulforaphane 150</title>
            <description>150 micromoles (26.6 mg) sulforaphane daily by mouth
Sulforaphane 150: 150 micromoles (26.6 mg) sulforaphane daily by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Bronchial Epithelial Cell Expression of AKR1C1 at 4 Weeks</title>
          <description>The fifth primary design variable is the change from baseline in expression of Aldo-Keto Reductase Family 1 Member C1 (AKR1C1) in bronchial epithelial cells (BEC) at 4 weeks. Three participants - one from each treatment group - were unable to complete follow-up bronchoalveolar lavage for primary outcome data.</description>
          <population>Number of participants analyzed based on number of individuals with alveolar macrophage samples in which assays could be successfully performed. Assays failed for two participants in the placebo group and two in the 150 micromole group.</population>
          <units>fold change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" lower_limit="0.84" upper_limit="1.98"/>
                    <measurement group_id="O2" value="1.08" lower_limit="0.85" upper_limit="2.14"/>
                    <measurement group_id="O3" value="0.79" lower_limit="0.53" upper_limit="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Applies to gene expression of Aldo-Keto Reductase Family 1 Member C1 (AKR1C1) in bronchial epithelial cells.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Bronchial Epithelial Cell Expression of AKR1C3 at 4 Weeks</title>
        <description>The sixth primary design variable is the change from baseline in expression of Aldo-Keto Reductase Family 1 Member C3 (AKR1C3) in bronchial epithelial cells (BEC) at 4 weeks. Three participants - one from each treatment group - were unable to complete follow-up bronchoalveolar lavage for primary outcome data.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>Number of participants analyzed based on number of individuals with bronchial epithelial samples in which assays could be successfully performed. Assays failed for two participants in the placebo group, one participant in the 25 micromole group, and one participant in the 150 micromole group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Microcrystalline cellulose
Placebo: Microcrystalline cellulose once daily by mouth</description>
          </group>
          <group group_id="O2">
            <title>Sulforaphane 25</title>
            <description>25 micromoles (4.4 mg) sulforaphane daily by mouth
Sulforaphane 25: 25 micromoles (4.4 mg) sulforaphane daily by mouth</description>
          </group>
          <group group_id="O3">
            <title>Sulforaphane 150</title>
            <description>150 micromoles (26.6 mg) sulforaphane daily by mouth
Sulforaphane 150: 150 micromoles (26.6 mg) sulforaphane daily by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Bronchial Epithelial Cell Expression of AKR1C3 at 4 Weeks</title>
          <description>The sixth primary design variable is the change from baseline in expression of Aldo-Keto Reductase Family 1 Member C3 (AKR1C3) in bronchial epithelial cells (BEC) at 4 weeks. Three participants - one from each treatment group - were unable to complete follow-up bronchoalveolar lavage for primary outcome data.</description>
          <population>Number of participants analyzed based on number of individuals with bronchial epithelial samples in which assays could be successfully performed. Assays failed for two participants in the placebo group, one participant in the 25 micromole group, and one participant in the 150 micromole group.</population>
          <units>fold change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" lower_limit="0.74" upper_limit="1.62"/>
                    <measurement group_id="O2" value="1.38" lower_limit="0.91" upper_limit="2.64"/>
                    <measurement group_id="O3" value="0.87" lower_limit="0.50" upper_limit="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Applies to gene expression of Aldo-Keto Reductase Family 1 Member C3 (AKR1C3) in bronchial epithelial cells.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fold-change in Isoprostane Concentrations (Follow-up to Baseline)</title>
        <description>Isoprostane, an oxidant stress indicator, was measured in expired breath condensate at baseline and 4 weeks.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>Number of participants analyzed based on number of individuals with expired breath condensate samples in which testing could be successfully performed. Samples were missing for two participants in the 25 micromole group and one participant in the 150 micromole group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Microcrystalline cellulose
Placebo: Microcrystalline cellulose once daily by mouth</description>
          </group>
          <group group_id="O2">
            <title>Sulforaphane 25</title>
            <description>25 micromoles (4.4 mg) sulforaphane daily by mouth
Sulforaphane 25: 25 micromoles (4.4 mg) sulforaphane daily by mouth</description>
          </group>
          <group group_id="O3">
            <title>Sulforaphane 150</title>
            <description>150 micromoles (26.6 mg) sulforaphane daily by mouth
Sulforaphane 150: 150 micromoles (26.6 mg) sulforaphane daily by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Fold-change in Isoprostane Concentrations (Follow-up to Baseline)</title>
          <description>Isoprostane, an oxidant stress indicator, was measured in expired breath condensate at baseline and 4 weeks.</description>
          <population>Number of participants analyzed based on number of individuals with expired breath condensate samples in which testing could be successfully performed. Samples were missing for two participants in the 25 micromole group and one participant in the 150 micromole group.</population>
          <units>fold change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.18" lower_limit="0.42" upper_limit="1.79"/>
                    <measurement group_id="O2" value="0.83" lower_limit="0.24" upper_limit="1.41"/>
                    <measurement group_id="O3" value="0.64" lower_limit="0.29" upper_limit="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.20</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fold-change in Serum Inflammatory Marker Concentrations (Follow-up to Baseline)</title>
        <description>Inflammatory markers were measured in serum samples derived from venipuncture at baseline and 4 weeks in the serum of the participants of the trial.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>Number of participants analyzed is based on number of participants that had plasma samples available. Samples were missing for one participant in the 25 micromole group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Microcrystalline cellulose
Placebo: Microcrystalline cellulose once daily by mouth</description>
          </group>
          <group group_id="O2">
            <title>Sulforaphane 25</title>
            <description>25 micromoles (4.4 mg) sulforaphane daily by mouth
Sulforaphane 25: 25 micromoles (4.4 mg) sulforaphane daily by mouth</description>
          </group>
          <group group_id="O3">
            <title>Sulforaphane 150</title>
            <description>150 micromoles (26.6 mg) sulforaphane daily by mouth
Sulforaphane 150: 150 micromoles (26.6 mg) sulforaphane daily by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Fold-change in Serum Inflammatory Marker Concentrations (Follow-up to Baseline)</title>
          <description>Inflammatory markers were measured in serum samples derived from venipuncture at baseline and 4 weeks in the serum of the participants of the trial.</description>
          <population>Number of participants analyzed is based on number of participants that had plasma samples available. Samples were missing for one participant in the 25 micromole group.</population>
          <units>fold change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C-reactive protein (mg/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" lower_limit="0.86" upper_limit="1.22"/>
                    <measurement group_id="O2" value="0.90" lower_limit="0.69" upper_limit="1.06"/>
                    <measurement group_id="O3" value="1.01" lower_limit="0.72" upper_limit="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin-6 (pg/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" lower_limit="0.65" upper_limit="1.19"/>
                    <measurement group_id="O2" value="0.90" lower_limit="0.76" upper_limit="1.08"/>
                    <measurement group_id="O3" value="1.12" lower_limit="0.88" upper_limit="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin-8 (pg/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" lower_limit="0.86" upper_limit="1.32"/>
                    <measurement group_id="O2" value="1.04" lower_limit="0.87" upper_limit="1.17"/>
                    <measurement group_id="O3" value="1.03" lower_limit="0.83" upper_limit="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Applies to C-reactive protein concentration</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.41</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Applies to Interleukin-6 concentration</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.07</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Applies to Interleukin-8 concentration</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.65</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fold-change in Inflammatory Marker Concentrations in Bronchial Alveolar Lavage (Follow-up to Baseline) by Treatment Group</title>
        <description>Inflammatory markers were measured in bronchial alveolar lavage samples at baseline and 4 weeks in the participants of this trial who had bronchoalveolar lavage samples obtained.Three participants - one from each treatment group - were unable to complete follow-up bronchoalveolar lavage.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>Number of participants analyzed is based on number of participants that had bronchial alveolar lavage samples available. Samples were missing for two participants in the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Microcrystalline cellulose
Placebo: Microcrystalline cellulose once daily by mouth</description>
          </group>
          <group group_id="O2">
            <title>Sulforaphane 25</title>
            <description>25 micromoles (4.4 mg) sulforaphane daily by mouth
Sulforaphane 25: 25 micromoles (4.4 mg) sulforaphane daily by mouth</description>
          </group>
          <group group_id="O3">
            <title>Sulforaphane 150</title>
            <description>150 micromoles (26.6 mg) sulforaphane daily by mouth
Sulforaphane 150: 150 micromoles (26.6 mg) sulforaphane daily by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Fold-change in Inflammatory Marker Concentrations in Bronchial Alveolar Lavage (Follow-up to Baseline) by Treatment Group</title>
          <description>Inflammatory markers were measured in bronchial alveolar lavage samples at baseline and 4 weeks in the participants of this trial who had bronchoalveolar lavage samples obtained.Three participants - one from each treatment group - were unable to complete follow-up bronchoalveolar lavage.</description>
          <population>Number of participants analyzed is based on number of participants that had bronchial alveolar lavage samples available. Samples were missing for two participants in the placebo group.</population>
          <units>fold change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Interleukin-8 (pg/mg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" lower_limit="0.68" upper_limit="2.75"/>
                    <measurement group_id="O2" value="0.94" lower_limit="0.52" upper_limit="2.22"/>
                    <measurement group_id="O3" value="1.11" lower_limit="0.42" upper_limit="2.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Secretory leukoprotease inhibitor (pg/mg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" lower_limit="0.83" upper_limit="1.90"/>
                    <measurement group_id="O2" value="1.09" lower_limit="0.85" upper_limit="1.49"/>
                    <measurement group_id="O3" value="1.12" lower_limit="0.65" upper_limit="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Applies to interleukin-8 results</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.71</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Applies to secretory leukoprotease inhibitor results</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.33</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fold-change in Plasma Inflammatory Marker Concentrations (Follow-up to Baseline)</title>
        <description>Inflammatory markers were measured in plasma at baseline and 4 weeks. Thiobarbituric acid reactive substances were measured in nmol malondialdehyde (MDA)/mL.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>Number of participants analyzed is based on number of participants that had plasma samples available. Samples were missing for one participant in the 25 micromole group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Microcrystalline cellulose
Placebo: Microcrystalline cellulose once daily by mouth</description>
          </group>
          <group group_id="O2">
            <title>Sulforaphane 25</title>
            <description>25 micromoles (4.4 mg) sulforaphane daily by mouth
Sulforaphane 25: 25 micromoles (4.4 mg) sulforaphane daily by mouth</description>
          </group>
          <group group_id="O3">
            <title>Sulforaphane 150</title>
            <description>150 micromoles (26.6 mg) sulforaphane daily by mouth
Sulforaphane 150: 150 micromoles (26.6 mg) sulforaphane daily by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Fold-change in Plasma Inflammatory Marker Concentrations (Follow-up to Baseline)</title>
          <description>Inflammatory markers were measured in plasma at baseline and 4 weeks. Thiobarbituric acid reactive substances were measured in nmol malondialdehyde (MDA)/mL.</description>
          <population>Number of participants analyzed is based on number of participants that had plasma samples available. Samples were missing for one participant in the 25 micromole group.</population>
          <units>fold change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Isoprostane (ng/mg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" lower_limit="0.55" upper_limit="1.22"/>
                    <measurement group_id="O2" value="0.90" lower_limit="0.63" upper_limit="1.74"/>
                    <measurement group_id="O3" value="0.88" lower_limit="0.55" upper_limit="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thiobarbituric acid reactive substances</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" lower_limit="0.77" upper_limit="1.19"/>
                    <measurement group_id="O2" value="1.05" lower_limit="0.88" upper_limit="1.17"/>
                    <measurement group_id="O3" value="1.06" lower_limit="0.84" upper_limit="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total antioxidants (mM Trolox equivalents/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" lower_limit="0.92" upper_limit="1.03"/>
                    <measurement group_id="O2" value="0.92" lower_limit="0.85" upper_limit="1.03"/>
                    <measurement group_id="O3" value="0.97" lower_limit="0.90" upper_limit="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Applies to isoprostane results.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.80</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Applies to thiobarbituric acid reactive substances results.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.35</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Applies to total antioxidants results.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.53</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Assessed via study questionnaires.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Microcrystalline cellulose
Placebo: Microcrystalline cellulose once daily by mouth</description>
        </group>
        <group group_id="E2">
          <title>Sulforaphane 25</title>
          <description>25 micromoles (4.4 mg) sulforaphane daily by mouth
Sulforaphane 25: 25 micromoles (4.4 mg) sulforaphane daily by mouth</description>
        </group>
        <group group_id="E3">
          <title>Sulforaphane 150</title>
          <description>150 micromoles (26.6 mg) sulforaphane daily by mouth
Sulforaphane 150: 150 micromoles (26.6 mg) sulforaphane daily by mouth</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD exacerbation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Poor appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Bad taste in mouth</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="29"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Bloating/gas</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="29"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Leg pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Increased phlegm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alexis Rea</name_or_title>
      <organization>Johns Hopkins University School of Medicine</organization>
      <phone>(443) 287-8496</phone>
      <email>area5@jhu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

